Otros idiomas Tyra Biosciences, Inc.

Acciones

TYRA

US90240B1061

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 08/05/2024			Varia. Cinco días.	Varia. 1 de enero.
18,03 ^USD	+0,50 %		-1,42 %	+30,18 %

07/05	Tyra Biosciences, Inc. anuncia cambios en su Junta Directiva	CI
21/03	TYRA BIOSCIENCES, INC. : HC Wainwright mantiene una recomendación de compra.	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors	07/05
Tyra Biosciences, Inc. Announces Board Changes	07/05
Tyra Biosciences Q4 Net Loss Widens	19/03
Tyra Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights	19/03
Tyra Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Tyra Biosciences to Present at Upcoming Investor Conferences	27/02
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference	07/02
Tyra Biosciences, Inc. announced that it has received $200.006021 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC	06/02
Sector Update: Health Care Stocks Advance Late Afternoon	02/02
Sector Update: Health Care	02/02
Tyra Biosciences Launches $200 Million Private Placement; Shares Rise	02/02
Top Midday Gainers	02/02
Tyra Biosciences Launches $200 Million Private Placement; Shares Rise	02/02
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing	02/02
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for Potential Achondroplasia Treatment	02/02
Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy	02/02
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia	01/02
Tyra Biosciences, Inc. Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia	01/02
Tyra Biosciences, Inc. announced that it expects to receive $200.006021 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC	01/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Tyra Biosciences, Inc.

Acciones

TYRA

US90240B1061

Otros idiomas

Filtros